<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742660</url>
  </required_header>
  <id_info>
    <org_study_id>KUH</org_study_id>
    <nct_id>NCT04742660</nct_id>
  </id_info>
  <brief_title>The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting</brief_title>
  <official_title>The Effect of Administration of Glycyrrhizin During Induction Period on the Occurrence of Postoperative Nausea and Vomiting After Breast Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators investigate the association between the administration of glycyrrhizin&#xD;
      during induction of general anesthesia and the occurrence of postoperative nausea and&#xD;
      vomiting (PONV) in patients undergo breast surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative nausea and vomiting (PONV) is one of a common complication after general&#xD;
      anesthesia with 30-50% of incidence, increased up to 80% in high risk group. The risk factors&#xD;
      of PONV include women population, the previous history of PONV, motion sickness in usual&#xD;
      life, non-smoker, exposure to inhalants, perioperative opioid and laparoscopic surgery. Women&#xD;
      population is a strong risk factor of PONV. Although perioperative management of PONV based&#xD;
      on a guideline has been done in a lot of medical centers worldwide, the incidence of PONV is&#xD;
      still reported relatively high.&#xD;
&#xD;
      The main ingredient of Glycyrrhizin is liquorice which has been used as antispasmodics,&#xD;
      antiemetics or treatment for gastric ulcer in oriental medicine. Utilizing these effects of&#xD;
      liquorice, the investigators investigate whether the addition of glycyrrhzin to conventional&#xD;
      antiemetics is effective to decrease the incidence of PONV and improvement of severity of&#xD;
      PONV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The anticipants are administered either ramosetron+placebo or ramosetron+glycyrrhizin</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants are blinded to allocated groups. Outcomes assessors are blinded to which group participants are assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of postoperative nausea and vomiting (PONV)</measure>
    <time_frame>up to 24 hours after discharge from postanesthetic care unit (PACU)</time_frame>
    <description>assessing the incidence of postoperative nausea and vomiting with ordinal scale (0=none, 1=nausea, 2=retching, 3= vomiting)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Postoperative Nausea</condition>
  <arm_group>
    <arm_group_label>group R</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants are administered a dose of 0.3mg of ramosetron (conventional antiemetics) intravenously followed by continuous infusion of 120mL normal saline at a rate of 10mL/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group G</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants are administered a dose of 0.3mg of ramosetron followed by continuous infusion of mixture of 20mL glycyrrhizin and 100mL normal saline (total 120mL) at a rate of 10mL/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ammonium Glycyrrhizinate</intervention_name>
    <description>In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.</description>
    <arm_group_label>group G</arm_group_label>
    <arm_group_label>group R</arm_group_label>
    <other_name>glycyrrhizin</other_name>
    <other_name>gulucolin S</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  participants scheduled to undergo breast surgery aged 20 and above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  aldosteronism&#xD;
&#xD;
          -  electrolyte imbalance&#xD;
&#xD;
          -  myopathies&#xD;
&#xD;
          -  drug addiction or suspected&#xD;
&#xD;
          -  bowel disease&#xD;
&#xD;
          -  allergy to drugs&#xD;
&#xD;
          -  smoker&#xD;
&#xD;
          -  taking any medications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Hyop Kim, M.D. Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yea-Ji Lee, M.D. Ph. D</last_name>
    <phone>+82-2-2030-5450</phone>
    <email>ladydaisy82@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sung-Hyop Kim, M.D. Ph.D</last_name>
    <phone>+82-2-2030-5454</phone>
    <email>yshkim75@kuh.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-T'ǔkpyǒlshi</state>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yea-Ji Lee</last_name>
      <phone>01086307701</phone>
      <email>ladydaisy82@naver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Yea-Ji Lee</investigator_full_name>
    <investigator_title>clinical assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycyrrhizic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

